Answers are grounded in this paper and cite their sources.
Treatment with obinutuzumab showed superior efficacy compared to placebo in active systemic lupus erythematosus patients, suggesting potential benefits.
Among adults with active SLE, treatment with obinutuzumab was superior to placebo with respect to the primary and all key secondary end points. (Funded by F. Hoffmann-La Roche; ALLEGORY ClinicalTrials.gov number, NCT04963296.).
No takes yet. Share an insight, caveat, or question.
Goldman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: